Vaseghi Marmar, Barwad Parag, Malavassi Corrales Federico J, Tandri Harikrishna, Mathuria Nilesh, Shah Rushil, Sorg Julie M, Gima Jean, Mandal Kaushik, Sàenz Morales Luis C, Lokhandwala Yash, Shivkumar Kalyanam
UCLA Cardiac Arrhythmia Center, University of California, Los Angeles, California; Neurocardiology Research Center of Excellence at UCLA, Los Angeles, California.
Holy Family Heart Institute, Holy Family Hospital, Mumbai, India.
J Am Coll Cardiol. 2017 Jun 27;69(25):3070-3080. doi: 10.1016/j.jacc.2017.04.035.
Cardiac sympathetic denervation (CSD) has been shown to reduce the burden of implantable cardioverter-defibrillator (ICD) shocks in small series of patients with structural heart disease (SHD) and recurrent ventricular tachyarrhythmias (VT).
This study assessed the value of CSD and the characteristics associated with outcomes in this population.
Patients with SHD who underwent CSD for refractory VT or VT storm at 5 international centers were analyzed by the International Cardiac Sympathetic Denervation Collaborative Group. Kaplan-Meier analysis was used to estimate freedom from ICD shock, heart transplantation, and death. Cox proportional hazards models were used to analyze variables associated with ICD shock recurrence and mortality after CSD.
Between 2009 and 2016, 121 patients (age 55 ± 13 years, 26% female, mean ejection fraction of 30 ± 13%) underwent left or bilateral CSD. One-year freedom from sustained VT/ICD shock and ICD shock, transplant, and death were 58% and 50%, respectively. CSD reduced the burden of ICD shocks from a mean of 18 ± 30 (median 10) in the year before study entry to 2.0 ± 4.3 (median 0) at a median follow-up of 1.1 years (p < 0.01). On multivariable analysis, pre-procedure New York Heart Association functional class III and IV heart failure and longer VT cycle lengths were associated with recurrent ICD shocks, whereas advanced New York Heart Association functional class, longer VT cycle lengths, and a left-sided-only procedure predicted the combined endpoint of sustained VT/ICD shock recurrence, death, and transplantation. Of the 120 patients taking antiarrhythmic medications before CSD, 39 (32%) no longer required them at follow-up.
CSD decreased sustained VT and ICD shock recurrence in patients with refractory VT. Characteristics independently associated with recurrence and mortality were advanced heart failure, VT cycle length, and a left-sided-only procedure.
在少数患有结构性心脏病(SHD)和复发性室性心律失常(VT)的患者中,心脏交感神经去神经支配术(CSD)已被证明可减轻植入式心律转复除颤器(ICD)电击的负担。
本研究评估了CSD的价值以及该人群中与预后相关的特征。
国际心脏交感神经去神经支配协作组分析了在5个国际中心因难治性VT或VT风暴接受CSD的SHD患者。采用Kaplan-Meier分析来估计无ICD电击、心脏移植和死亡的生存率。使用Cox比例风险模型分析与CSD后ICD电击复发和死亡率相关的变量。
2009年至2016年间,121例患者(年龄55±13岁,26%为女性,平均射血分数为30±13%)接受了左侧或双侧CSD。1年无持续性VT/ICD电击、ICD电击、移植和死亡的生存率分别为58%和50%。CSD将ICD电击负担从研究入组前一年的平均18±30次(中位数10次)降至中位随访1.1年时的2.0±4.3次(中位数0次)(p<0.01)。多变量分析显示,术前纽约心脏协会功能分级为III级和IV级的心力衰竭以及较长的VT周期与ICD电击复发相关,而纽约心脏协会功能分级晚期、较长的VT周期以及仅左侧手术则预测了持续性VT/ICD电击复发、死亡和移植的联合终点。在CSD前服用抗心律失常药物的120例患者中,39例(32%)在随访时不再需要这些药物。
CSD降低了难治性VT患者的持续性VT和ICD电击复发率。与复发和死亡率独立相关的特征是晚期心力衰竭、VT周期长度和仅左侧手术。